Loading...
Documents
-
Angeline Ginzac, Ioana Molnar, Xavier Durando, Thibault de La Motte Rouge, Thierry Petit, et al.. Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. Breast Cancer Research and Treatment, 2024, ⟨10.1007/s10549-024-07285-y⟩. ⟨hal-04495069⟩
-
Imène Mansouri, Rodrigue S Allodji, Catherine Hill, Chiraz El‐fayech, François Pein, et al.. The role of irradiated heart and left ventricular volumes in heart failure occurrence after childhood cancer. European Journal of Heart Failure, 2018, 21 (4), pp.509 - 518. ⟨10.1002/ejhf.1376⟩. ⟨inserm-04439245⟩
-
Thomas Sarrade, Rodrigue Allodji, Youssef Ghannam, Guillaume Auzac, Sibille Everhard, et al.. CANTO-RT: One of the Largest Prospective Multicenter Cohort of Early Breast Cancer Patients Treated with Radiotherapy including Full DICOM RT Data. Cancers, 2023, 15 (3), pp.751. ⟨10.3390/cancers15030751⟩. ⟨inserm-04438144⟩
-
Stéphane Culine, Valentin Harter, Gwenaelle Gravis, Aude Fléchon, Christine Chevreau, et al.. Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial. Clinical Genitourinary Cancer, 2021, 19 (6), pp.554-562. ⟨10.1016/j.clgc.2021.08.005⟩. ⟨hal-03625944⟩
-
Thomas Grinda, Alison Antoine, William Jacot, Paul-Henri Cottu, Thibault de la Motte Rouge, et al.. Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort. European Journal of Cancer, 2023, 189, pp.112935. ⟨10.1016/j.ejca.2023.05.023⟩. ⟨hal-04205902⟩
-
Renaud Sabatier, Jean-Yves Pierga, Hervé Curé, Rakan Abulnaja, Eric Lambaudie, et al.. Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial. Cancers, 2021, 13 (1), pp.140. ⟨10.3390/cancers13010140⟩. ⟨hal-03622751⟩
-
Elise Dumas, Lucie Laot, Florence Coussy, Beatriz Grandal Rejo, Eric Daoud, et al.. The French Early Breast Cancer Cohort (FRESH): A Resource for Breast Cancer Research and Evaluations of Oncology Practices Based on the French National Healthcare System Database (SNDS). Cancers, 2022, 14 (11), pp.2671. ⟨10.3390/cancers14112671⟩. ⟨hal-03901737⟩
-
Paul Gougis, Arthur Géraud, Marc Hilmi, Aurore Vozy, Luca Campedel, et al.. Cytochrome P-450-mediated herb and food–drug interactions can be identified in cancer patients through patient self-reporting with a tablet application: results of a prospective observational study. ESMO Open, 2022, 7 (6), ⟨10.1016/j.esmoop.2022.100650⟩. ⟨hal-03950147⟩
-
Karim Fizazi, Gero Kramer, Jean-Christophe Eymard, Cora N Sternberg, Johann de Bono, et al.. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. Lancet Oncology, 2020, 21, pp.1513 - 1525. ⟨10.1016/S1470-2045(20)30449-6⟩. ⟨hal-03493378⟩
-
Thi Tran, Jean-Remi Lavillegrand, Cedric Lereverend, Bruno Esposito, Lucille Cartier, et al.. Mild dyslipidemia accelerates tumorigenesis through expansion of Ly6Chi monocytes and differentiation to pro-angiogenic myeloid cells. Nature Communications, 2022, 13 (1), pp.5399. ⟨10.1038/s41467-022-33034-0⟩. ⟨inserm-03788301⟩
-
Christian Carrie, Nicolas Magné, Patricia Burban-Provost, Paul Sargos, Igor Latorzeff, et al.. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncology, 2019, 20, pp.1740 - 1749. ⟨10.1016/S1470-2045(19)30486-3⟩. ⟨hal-03489049⟩
-
Lidia Delrieu, Anne-Sophie Hamy, Florence Coussy, Amyn Kassara, Bernard Asselain, et al.. Digital phenotyping in young breast cancer patients treated with neoadjuvant chemotherapy (the NeoFit Trial): protocol for a national, multicenter single-arm trial. BMC Cancer, 2022, 22 (1), pp.493. ⟨10.1186/s12885-022-09608-y⟩. ⟨inserm-03692232⟩